Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis

The purpose of this study is to determine the efficacy of adjuvant HIPEC with Mitomycin C after colectomy in the treatment of colorectal cancer patients at high risk of peritoneal carcinomatosis.

Trial Details

NCT ID

NCT04370925

Phase

PHASE3

Sponsor

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

Radical colectomy
HIPEC
Systemic chemotherapy

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723
Beijing, Beijing Municipality, China|39.9075,116.39723
Beijing, Beijing Municipality, China|39.9075,116.39723
Beijing, Beijing Municipality, China|39.9075,116.39723
Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

Age between 18 and 70 years
Nonpregnant or breast-feeding women
ECOG status 0-1
Colorectal adenocarcinoma or mucinous adenocarcinoma;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →